NovoCure Limited (NVCR) CEO Sells $1,432,232.44 in Stock

NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 94,102 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $15.22, for a total value of $1,432,232.44. Following the transaction, the chief executive officer now owns 1,069,496 shares of the company’s stock, valued at approximately $16,277,729.12. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Asaf Danziger also recently made the following trade(s):

  • On Friday, June 16th, Asaf Danziger sold 42,457 shares of NovoCure Limited stock. The shares were sold at an average price of $15.15, for a total value of $643,223.55.
  • On Monday, June 12th, Asaf Danziger sold 180,601 shares of NovoCure Limited stock. The shares were sold at an average price of $15.13, for a total value of $2,732,493.13.

NovoCure Limited (NVCR) opened at 15.80 on Tuesday. The stock’s market cap is $1.39 billion. NovoCure Limited has a one year low of $5.95 and a one year high of $15.85. The stock has a 50 day moving average price of $12.91 and a 200-day moving average price of $9.38.

NovoCure Limited (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04. The company had revenue of $34.88 million for the quarter, compared to analysts’ expectations of $39.46 million. NovoCure Limited had a negative return on equity of 74.31% and a negative net margin of 109.30%. Equities research analysts expect that NovoCure Limited will post ($0.80) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

TRADEMARK VIOLATION NOTICE: “NovoCure Limited (NVCR) CEO Sells $1,432,232.44 in Stock” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2655016/novocure-limited-nvcr-ceo-sells-1432232-44-in-stock.html.

A number of brokerages have recently commented on NVCR. Wells Fargo & Company upgraded NovoCure Limited from a “market perform” rating to an “outperform” rating and set a $15.00 target price for the company in a report on Wednesday, May 24th. JMP Securities reiterated an “outperform” rating and issued a $34.00 target price on shares of NovoCure Limited in a report on Tuesday, April 4th. Deutsche Bank AG lifted their target price on NovoCure Limited from $10.00 to $11.00 and gave the stock a “hold” rating in a report on Friday, April 28th. Zacks Investment Research upgraded NovoCure Limited from a “sell” rating to a “hold” rating in a report on Tuesday, February 28th. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 target price on shares of NovoCure Limited in a report on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $16.25.

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in shares of NovoCure Limited by 61.7% in the first quarter. Bank of America Corp DE now owns 37,531 shares of the medical equipment provider’s stock valued at $305,000 after buying an additional 14,321 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of NovoCure Limited by 14.6% in the first quarter. Geode Capital Management LLC now owns 128,632 shares of the medical equipment provider’s stock valued at $1,041,000 after buying an additional 16,411 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of NovoCure Limited by 12.0% in the first quarter. Vanguard Group Inc. now owns 3,047,940 shares of the medical equipment provider’s stock valued at $24,688,000 after buying an additional 325,512 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of NovoCure Limited by 3.3% in the first quarter. Teachers Advisors LLC now owns 98,799 shares of the medical equipment provider’s stock valued at $800,000 after buying an additional 3,125 shares during the last quarter. Finally, River & Mercantile Asset Management LLP bought a new stake in shares of NovoCure Limited during the first quarter valued at about $937,000. Institutional investors and hedge funds own 24.19% of the company’s stock.

NovoCure Limited Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:NVCR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback


© 2006-2017 Ticker Report. Google+.